The University of Southampton
University of Southampton Institutional Repository

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases
Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases
Tyrosine kinases play key roles in cell proliferation, survival and differentiation. Their aberrant activation, caused either by the formation of fusion genes by chromosome translocation or by intragenic changes, such as point mutations or internal duplications, is of major importance in the development of many haematological malignancies. An understanding of the mechanisms by which BCR-ABL contributes to the pathogenesis of chronic myeloid leukaemia led to the development of imatinib, the first of several tyrosine kinase inhibitors to enter clinical trials. Although the development of resistance has been problematic, particularly in aggressive disease, the development of novel inhibitors and combination with other forms of therapy shows promise.
Abbreviations: ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CEL, chronic eosinophilic leukaemia; CML, chronic myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; EGFR, epidermal growth factor receptor; EMS, Eight p11 myeloproliferative syndrome; EPO, erythropoietin; FGFR, fibroblast growth factor receptor; FIP1L1, Fip1-like 1; FLT3, Fms-like tyrosine kinase 3; FISH, fluorescence in situ hybridization; HES, hypereosinophilic syndrome; IFNa, interferon a; IL3, interleukin 3; IRIS, International Randomized study of Interferon and STI571; ITD, internal tandem duplication; JAK, Janus kinase; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NTRK, neurotrophin receptor kinase; PDGFR, platelet-derived growth factor receptor; Ph, Philadelphia chromosome; PV, polycythaemia vera; RT, reverse transcription; SCT, stem cell transplantation; TK, tyrosine kinase.
BCR-ABL, haematological malignancy, imatinib, leukaemia, signalling inhibitor, tyrosine kinase
0143-5221
233-249
Chase, Andrew
a40a09c2-3073-4655-ba0b-a802e34914b5
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Chase, Andrew
a40a09c2-3073-4655-ba0b-a802e34914b5
Cross, Nicholas C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4

Chase, Andrew and Cross, Nicholas C.P. (2006) Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Clinical Science, 111 (4), 233-249. (doi:10.1042/CS20060035).

Record type: Article

Abstract

Tyrosine kinases play key roles in cell proliferation, survival and differentiation. Their aberrant activation, caused either by the formation of fusion genes by chromosome translocation or by intragenic changes, such as point mutations or internal duplications, is of major importance in the development of many haematological malignancies. An understanding of the mechanisms by which BCR-ABL contributes to the pathogenesis of chronic myeloid leukaemia led to the development of imatinib, the first of several tyrosine kinase inhibitors to enter clinical trials. Although the development of resistance has been problematic, particularly in aggressive disease, the development of novel inhibitors and combination with other forms of therapy shows promise.
Abbreviations: ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CEL, chronic eosinophilic leukaemia; CML, chronic myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; EGFR, epidermal growth factor receptor; EMS, Eight p11 myeloproliferative syndrome; EPO, erythropoietin; FGFR, fibroblast growth factor receptor; FIP1L1, Fip1-like 1; FLT3, Fms-like tyrosine kinase 3; FISH, fluorescence in situ hybridization; HES, hypereosinophilic syndrome; IFNa, interferon a; IL3, interleukin 3; IRIS, International Randomized study of Interferon and STI571; ITD, internal tandem duplication; JAK, Janus kinase; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; NTRK, neurotrophin receptor kinase; PDGFR, platelet-derived growth factor receptor; Ph, Philadelphia chromosome; PV, polycythaemia vera; RT, reverse transcription; SCT, stem cell transplantation; TK, tyrosine kinase.

Full text not available from this repository.

More information

Published date: 3 April 2006
Keywords: BCR-ABL, haematological malignancy, imatinib, leukaemia, signalling inhibitor, tyrosine kinase

Identifiers

Local EPrints ID: 59561
URI: http://eprints.soton.ac.uk/id/eprint/59561
ISSN: 0143-5221
PURE UUID: dfe9f34e-1bc3-491a-91a2-a442a471928a
ORCID for Nicholas C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 03 Sep 2008
Last modified: 10 Dec 2019 01:47

Export record

Altmetrics

Contributors

Author: Andrew Chase

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×